SN-38

Generic Name: SN-38

Brand Names: Trodelvy

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₀N_₂O_₅

CAS Number: 86639-52-3

Unique Ingredient Identifier: 0H43101T0J

Background: 7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan Irinotecan, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negat...

Indication: Investigated for use/treatment in colorectal cancer.

Associated Conditions: Hormone Receptor Positive Metastatic Breast Cancer, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Triple Negative Breast Cancers, Unresectable Triple-Negative Breast Carcinoma, Metastatic HR Positive, HER2/Neu Negative Breast Cancer, Unresectable Locally Advanced Triple-negative Breast Cancer, Unresectable, locally advanced HR Positive, HER2/Neu Negative Breast Cancer, Unresectable, locally advanced Hormone Receptor Positive Breast Carcinoma

Associated Therapies: -

Clinical Trials

Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

Phase 1

Active, not recruiting

Conditions: Esophagogastric Adenocarcinoma

Interventions: Drug: Sacituzumab govitecan

First Posted Date: 2023-11-08

Last Posted Date: 2024-11-11

Lead Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Target Recruit Count: 56

Registration Number: NCT06123468

Locations: 🇦🇹
SCRI-CCCIT GmbH, Salzburg, Austria
🇩🇪
Hämatologisch-Onkologische Praxis Eppendorf, Hamburg, Germany
🇩🇪
Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany

and more 5 locations

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer
Advanced Breast Cancer

Interventions: Drug: Organoid-guided treatment
Drug: Taxane
Drug: Capecitabine
Drug: Gemcitabine
Drug: Vinorelbine
Drug: Eribulin
Drug: Anthracycline
Drug: Carboplatin
Drug: Utidelone
Drug: Trastuzumab deruxtecan
Drug: Sacituzumab govitecan

First Posted Date: 2023-10-26

Last Posted Date: 2024-11-25

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 252

Registration Number: NCT06102824

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Phase 2

Recruiting

Conditions: Her 2 Positive Breast Cancer
Breast Cancer Metastatic
Breast Cancer Female

Interventions: Drug: Sacituzumab Govitecan
Drug: Trastuzumab
Drug: Trastuzumab and Hyaluronidase-oysk

First Posted Date: 2023-10-25

Last Posted Date: 2024-05-30

Lead Sponsor: Adrienne G. Waks

Target Recruit Count: 40

Registration Number: NCT06100874

Locations: 🇺🇸
DFCI @ South Shore Hospital, South Weymouth, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institite, Boston, Massachusetts, United States

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Sacituzumab govitecan
Drug: Pembrolizumab

First Posted Date: 2023-10-13

Last Posted Date: 2024-11-13

Lead Sponsor: West German Study Group

Target Recruit Count: 348

Registration Number: NCT06081244

Locations: 🇩🇪
Kliniken Essen-Mitte, Klinik für Senologie/Interdisziplinäres Brustzentrum, Essen, NRW, Germany
🇩🇪
Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, Mönchengladbach, NRW, Germany

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Lung Cancer

Interventions: Drug: Sacituzumab Govitecan
Drug: Pembrolizumab

First Posted Date: 2023-09-26

Last Posted Date: 2024-02-29

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 37

Registration Number: NCT06055465

Locations: 🇭🇰
Department of Oncology, Princess Margaret Hospital, Hong Kong, Hong Kong
🇭🇰
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
🇭🇰
Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong

and more 1 locations

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Phase 2

Recruiting

Conditions: Ovarian Carcinoma

Interventions: Drug: Sacituzumab govitecan

First Posted Date: 2023-09-08

Last Posted Date: 2024-10-07

Lead Sponsor: Yale University

Target Recruit Count: 20

Registration Number: NCT06028932

Locations: 🇺🇸
Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Phase 2

Recruiting

Conditions: Gland
Salivary Gland Cancers

Interventions: Drug: Sacituzumab Govitecan

First Posted Date: 2023-06-01

Last Posted Date: 2024-10-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT05884320

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Phase 3

Active, not recruiting

Conditions: Locally Advanced or Unresectable Metastatic Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel
Drug: Nab-paclitaxel
Drug: Capecitabine

First Posted Date: 2023-05-03

Last Posted Date: 2024-08-29

Lead Sponsor: Gilead Sciences

Target Recruit Count: 654

Registration Number: NCT05840211

Locations: 🇰🇷
Samsung Medical Center, Gangnam-Gu, Korea, Republic of
🇲🇽
Centro de Atención e Investigación Clínica en Oncología, Yucatán, Mexico
🇵🇱
Wojewodzki Szpital Specjalistyczny lm. Stefana Kardynala Wyszynsklego SPZOZ w Lublinie, Lublin, Poland

and more 283 locations